AEON Biopharma (AEON) Operating Expenses (2021 - 2026)

AEON Biopharma has disclosed Operating Expenses across 6 years of filings, most recently posting $5.9 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 36.45% year-over-year to $5.9 million; the TTM figure through Jun 2026 stood at $18.3 million (up 63.97% YoY), while the FY2025 annual figure was $12.8 million, up 117.54% from the prior year.
• Operating Expenses came in at $5.9 million for Q2 2026 at AEON Biopharma, up from $5.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $283.7 million in Q3 2023 to a low of -$153.5 million in Q2 2024.
• Average Operating Expenses over 5 years is $17.6 million, with a median of $4.9 million recorded in 2025.
• Year-over-year, Operating Expenses surged 3253.1% in 2023 and tumbled 1198.51% in 2024.
• Over 5 years, Operating Expenses stood at $15.0 million in 2022, then surged by 1787.27% to $283.7 million in 2023, then slumped by 99.18% to $2.3 million in 2024, then soared by 137.44% to $5.5 million in 2025, then gained by 7.4% to $5.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $5.9 million in Q2 2026, $5.5 million in Q4 2025, and $2.5 million in Q3 2025.